跳至主要内容
临床试验/NCT01353079
NCT01353079已完成3 期

Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen

Greer Laboratories2 个研究点 分布在 1 个国家目标入组 429 人开始时间: 2011年4月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
429
试验地点
2
主要终点
Scores on a Scale [Net Average Combined Daily Rhinoconjunctivitis Symptom (RSS) and Medication Scores]

研究概览

简要总结

The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • allergic to ragweed

排除标准

  • not allergic to ragweed
  • history of anaphylaxis
  • subject with chronic sinusitis, unstable angina, significant arrhythmia, uncontrolled hypertension, or other chronic or immunological disease
  • Asthmatic subjects with FEV1 or PEF less than or equal to 80% predicted
  • Subjects who have received experimental drug within 30 days prior to study admission
  • Subjects who have received anit-IgE medications in the last 12 months
  • Subjects who have received ragweed immunotherapy in the last 3 years
  • Subjects who are currently users of inhaled, intramuscular, or intravenous corticosteroids, tricyclic anti-depressants, beta blockers, and MAO inhibitors
  • Subjects refusing to sign epi-pen training form
  • Females who are pregnant or breast feeding

结局指标

主要结局

Scores on a Scale [Net Average Combined Daily Rhinoconjunctivitis Symptom (RSS) and Medication Scores]

时间窗: 2011 ragweed pollen season, 8/2011 -10/2011

Change in baseline in avg combined daily RSS and medication scores during entire ragweed season in ITT population. Symptom score: sum of scores from 8 symptoms rated 0-3 (0=absent, 1=mild, 2=moderate, 3=severe), ocular (itchiness, swelling/redness, and watery eyes/tears), nasal (sneezing, itching, runny and stuffy nose), and ears (itching). Avg daily RSS computed by: (1) summing 8 individual allergy symptoms recorded in AM and PM; (2) forming daily RSS by summing AM and PM RSS for each day of ragweed season; (3) averaging daily RSS for entire ragweed season.Total allergy relief medication score computed by summing individual medication scores. Relief medication scores: 0-no medication taken; 1-using once daily oral antihistamine; 1-using once daily ocular antihistamine; 1-treatment with albuterol. Maximum medication score dependent on cumulative rescue medication use. Lower result is more favorable. Avg daily Combined Score Range: 0 (min) - 51 (max); lower score was more favorable.

次要结局

  • Scores on a Scale (Net Average Combined Daily Rhinoconjunctivitis Symptom and Medication Scores Reported During the Three Peak Weeks of Ragweed Pollen Season)(3 peak weeks of the 2011 ragweed pollen season)
  • Scores of a Scale (Average Daily Rhinoconjunctivitis Symptom Scores During the Entire Ragweed Pollen Season)(2011 ragweed pollen season; 8/2011 - 10/2011)
  • Scores on a Scale (Average Daily Rhinoconjunctivitis Symptom Scores During the Three Peak Weeks of Ragweed Pollen Season)(3 peak weeks of the 2011 ragweed pollen season)

研究者

发起方
Greer Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Efficacy and Safety Study Of Short Ragweed Pollen... | 临床试验